Related Experiment Video
Updated: Feb 11, 2026
Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
Published on: February 12, 2021
[Study of TRAIL receptors expression on the mononuclear cells from multiple myeloma patients and KM3 cells]
Juan Li1, Jun-He Li, Shao-Kai Luo
1Department of Hematology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Objective:
To study the differential expression of four TRAIL receptors on bone marrow mononuclear cells (BMMNC) from multiple myeloma (MM) patients and myeloma cell line KM3 cells, to compare their altered expressions after chemotherapy and to explore the mechanisms by which TRAIL selectively kills tumor cells.
Methods:
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry were used to investigate the expression of four TRAIL receptors on BMMNCs in 23 MM patients, KM3 cells and 15 controls, and the changes of their expression pattern after chemotherapy and after incubation of KM3 cells with sub-clinical concentration of doxorubicin.
Results:
DR4 and DR5 were highly expressed on KM3 cells with no expression of DcR1 and DcR2. Expressions of DR4 and DR5 on BMMNCs from MM patients were higher and expression of DcR1 and DcR2 were lower than that of controls (P < 0.05). The expression of DR5 on MM and KM3 cells was up-regulated after chemotherapy and exposure to doxorubicin (P < 0. 05).
Conclusions:
The expressions of four TRAIL receptors on myeloma cells and normal controls were different, which might account for the selective killing effect of TRAIL on MM cells. Up-regulated DR5 on KM3 cells after incubating with doxorubicin and after chemotherapy suggests the cytotoxic agents might enhance the apoptosis of MM cells.
Insights
TRAIL receptor expression differs between multiple myeloma (MM) cells and normal cells, explaining TRAIL
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Context:
- Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of plasma cells.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors play a crucial role in apoptosis.
- Understanding TRAIL receptor expression is vital for developing targeted therapies in MM.
Purpose:
- To investigate the differential expression of four TRAIL receptors (DR4, DR5, DcR1, DcR2) on bone marrow mononuclear cells (BMMNCs) from MM patients and the KM3 myeloma cell line.
- To compare TRAIL receptor expression in MM patients and controls.
- To analyze alterations in TRAIL receptor expression following chemotherapy and doxorubicin treatment.
Summary:
- DR4 and DR5 were highly expressed on KM3 cells, while DcR1 and DcR2 showed no expression.
- MM patient BMMNCs exhibited higher DR4 and DR5 expression and lower DcR1 and DcR2 expression compared to controls.
- Chemotherapy and doxorubicin treatment upregulated DR5 expression on MM and KM3 cells.
Impact:
- Differential TRAIL receptor expression may explain TRAIL's selective killing of MM cells.
- Upregulation of DR5 suggests that cytotoxic agents can enhance MM cell apoptosis via TRAIL pathways.
- Findings support the potential of TRAIL-based therapies in multiple myeloma treatment.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
01:58Cell Specific Gene Expression
01:58Cell Specific Gene Expression
02:24Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
02:24Regulation of Expression Occurs at Multiple Steps
01:23Regulation of Expression at Multiple Steps
01:28Types of Receptors: Cell Surface Receptors